Tacrolimus, Prograf®
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Renal Transplantation
Conditions
Renal Transplantation
Trial Timeline
Jan 1, 2003 → Mar 1, 2006
NCT ID
NCT00297765About Tacrolimus, Prograf®
Tacrolimus, Prograf® is a approved stage product being developed by Astellas Pharma for Renal Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00297765. Target conditions include Renal Transplantation.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00297765 | Approved | Completed |
Competing Products
20 competing products in Renal Transplantation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109 | MBX Biosciences | Phase 1 | 28 |
| LY3473329 | Eli Lilly | Phase 1 | 33 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont | Spruce Biosciences | Phase 2 | 44 |
| Drotrecogin alfa activated (Xigris) | Eli Lilly | Phase 2 | 52 |
| LY3819469 | Eli Lilly | Phase 1 | 33 |
| Atezolizumab + Cabozantinib | Chugai Pharmaceutical | Phase 3 | 77 |
| DS-6000a + DS-6000a | Daiichi Sankyo | Phase 1 | 33 |
| DS-1093a | Daiichi Sankyo | Phase 1 | 33 |
| CS-3150 | Daiichi Sankyo | Phase 3 | 77 |
| AGS-16C3F | Astellas Pharma | Phase 1 | 33 |
| AGS-16M8F | Astellas Pharma | Phase 1 | 33 |
| CP-461 | Astellas Pharma | Phase 2 | 52 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| YM178 | Astellas Pharma | Phase 1 | 33 |
| intravenous immunoglobulins (IVIG) | Astellas Pharma | Phase 1 | 33 |
| bixalomer | Astellas Pharma | Pre-clinical | 23 |